A personalized approach for anti-CD20 therapies in multiple sclerosis

B-cell depleting therapies are frequently used as high efficacy treatments for multiple sclerosis (MS). We will elaborate on current data and future perspectives of one of the most studied anti-CD20 therapies concerning personalization. Currently, multiple randomized controlled trails are recruiting patients, with three different treatment strategies concerning the dose or the dosing interval of ocrelizumab. These strategies involve higher dosing, B-cell tailored dosing and discontinuation of ocrelizumab. We propose a roadmap (Figure 1), that will incorporate results of current trials to address the current knowledge gaps in pursuit of a more efficient use of anti-CD20 therapies in MS.